Josep M. Llovet

1954 -

pays de nationalité: Espagne

langues parlées, écrites ou signées: espagnol

scolarité: université autonome de Barcelone, université de Barcelone

occupation: chercheur ou chercheuse

Séries

Il n'y a rien à voir ici

Créer une nouvelle série

Œuvres

Il n'y a rien à voir ici

Créer une nouvelle œuvre

Articles 251

Date

Titre

Auteur·ices

2022-08-23

Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents

Laura Torrens, Miguel Torres-Martín, Thais Leonel, Mireia García-López, Wei Qiang Leow, Patricia Taik, Genis Camprecios, Sofía Pérez-del-Pulgar, Eric Letouzé, Jessica Zucman-Rossi, Andrew V Uzilov, Xavier Forns, Josep M. Llovet
2021-03-24

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Marta Szydlowska, Aleksandra Deczkowska, Daniela Lenggenhager, Anja Moncsek, Donato Inverso, Indrabahadur Singh, Michele Vacca, Fabio Marra, Michael Allison, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Ann K Daly, Bernhard Scheiner, Katharina Pomej, Markus Peck-Radosavljevic, Jan-Philipp Mallm, Andrea Schietinger, Hellmut G Augustin, Beat Peter Müller-Stich, Hiroto Kikuchi, Dan G Duda, Henrik E Mei, Axel Ronald Schulz, Marc Ringelhan, Amaia Lujambio, Jean-François Dufour, Masatoshi Kudo, Nabil Djouder, Patrice N Marche, David J. Pinato, Roland Rad, Joachim C. Mertens, Achim Weber, Felix Meissner, Quentin M Anstee, Ido Amit, Percy A. Knolle, Burkhard Becher, Josep M. Llovet, Mathias Heikenwalder
2021-12-29

Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma

Caner Ercan, Sandro Nuciforo, Sofía Pérez-del-Pulgar, Sergio Rodríguez-Tajes, Savas D Soysal, Josep M. Llovet, Augusto Villanueva, Luigi M Terracciano, Markus H Heim, Charlotte K Y Ng, Salvatore Piscuoglio
2020-01-15

Intratumoral heterogeneity and clonal evolution in liver cancer

Mehmet Eren Ahsen, Johann von Felden, Ismail Labgaa, Teresa Garcia-Lezana, Eric E Schadt, Myron Schwartz, Josep M. Llovet, Augusto Villanueva, Robert Sebra
2020-02-01

mRECIST for HCC: Performance and novel refinements

Josep M. Llovet
2020-05-20

Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference

Josep M. Llovet
2020-09-01

Copy number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma

Laia Bassaganyas, Laura Torrens, Catherine E Willoughby, Sebastià Franch-Expósito, Jordi Camps, Josep M. Llovet
2020-10-23

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Johann von Felden, Ismail Labgaa, Myron Schwartz, Josep M. Llovet, Augusto Villanueva
2019-08-01

New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

Josep M. Llovet
2019-01-07

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC

Roser Pinyol, Josep M. Llovet
2019-01-18

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Josep M. Llovet, Guido Gerken
2019-05-01

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Josep M. Llovet
2019-02-06

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma

Josep M. Llovet, Jordi Bruix, Gerold Meinhardt
2019-07-09

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

Roser Pinyol, Josep M. Llovet
2019-07-22

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents

Roser Pinyol, Josep M. Llovet
2019-06-11

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma

Marina Ruiz de Galarreta, Marc Puigvehí, María Casanova-Acebes, Maxime Dhainaut, Johann von Felden, Alice O Kamphorst, Josep M. Llovet, Amaia Lujambio, Miriam Merad
2019-04-01

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Mohsen Malehmir, Marta Szydlowska, Donato Inverso, Carsten Deppermann, David Stegner, Patrick M Helbling, César Nombela-Arrieta, Martina Hinterleitner, Chris J Weston, David Adams, Natasha S Anstee, Malte N Bongers, Dominic J Withers, Jerry Ware, Michael D Milsom, Adam J. Rose, Josep M. Llovet, Roser Pinyol, Matthias S Matter, Nabil Djouder, Paul Kubes, Percy A. Knolle, Meinrad Gawaz, Achim Weber, Mathias Heikenwalder, Marco Prinz
2019-08-12

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

Théo Z Hirsch, Julien Calderaro, Sandra Rebouissou, Josep M. Llovet, Jessica Zucman-Rossi, Gabrielle Couchy, Laurence Chiche, Jean Charles Nault, Yoann Martin, Guillaume Morcrette, Paulette Bioulac-Sage
2019-04-01

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

Josep M. Llovet
2019-03-31

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

Josep M. Llovet, Augusto Villanueva
2019-09-01

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma

Mark Yarchoan, Josep M. Llovet, John Groopman, Hashem El-Serag, Lewis R. Roberts, Elizabeth Jaffee, Michael Karin
2018-10

Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008]

Jordi Bruix, Josep M. Llovet, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Ann-Lii Cheng
2018-08-14

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Roser Pinyol, Laia Bassaganyas, Norihiro Kokudo, Agrin Moeini, Umberto Cillo, Augusto Villanueva, Jordi Bruix, Josep M. Llovet, Vincenzo Mazzaferro, Manel Solé, Daniela Sia, Swan N Thung, Sasan Roayaie, Gar-Yang Chau, Gerold Meinhardt, Han Chu Lee, Joong-Won Park
2018-10-01

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Tomás Pascual, Elísabeth Pérez Ruiz, Carme Font, Montserrat Muñoz, Manel Juan, Josep M. Llovet
2018-01-12

Beta-catenin cleavage enhances transcriptional activation

Josep M. Llovet, Qing-Bai She, Linheng Li
2018-04-09

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma

Josep M. Llovet, Ismail Labgaa, Johann von Felden, Sebastiao N Martins-Filho, Scott L. Friedman, Augusto Villanueva
2018-02-01

Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Josep M. Llovet
2018-06-14

Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors

Josep M. Llovet
2018-06-27

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

Yuk Ting Ma, Judit Kocsis, Jean-François Dufour, Markus Peck-Radosavljevic, Winnie Yeo, Josep M. Llovet, Satawat Thongsawat, Wattana Sukeepaisarnjaroen
2018-10-01

Molecular therapies and precision medicine for hepatocellular carcinoma

Josep M. Llovet
2017-06-14

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

Josep M. Llovet, Laia Bassaganyas, Manuel Castro de Moura, Vincenzo Mazzaferro, Manel Esteller i Badosa, Augusto Villanueva, Juan Putra, Samuel Waxman
2017-01-25

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Josep M. Llovet, Thomas Decaens, Valérie Boige, José Ríos, Ferran Torres, Masatoshi Kudo

Humain - wd:Q37393125

Bienvenue sur Inventaire

la bibliothèque de vos ami⋅e⋅s et communautés